The FDA has approved Taclonex, a combination topical consisting of calcipotriene 0.005% and betamethasone dipropionate 0.064%, for the treatment of psoriasis vulgaris in adults. Warner Chilcott plans to launch the new ointment in the first half of 2006.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.